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Abstract 
Background: MicroRNAs (miRNAs) are promising biomarkers due to their structural stability and distinct expres‑
sion profile in various cancers. We wanted to explore the miRNA expression in benign breast tissue and breast cancer 
subgroups in the Norwegian Women and Cancer study.
Methods: Specimens and histopathological data from study participants in Northern Norway diagnosed with breast 
cancer, and benign tissue from breast reduction surgery were collected. Main molecular subtypes were based on 
surrogate markers; luminal A (ER+ and/or PR+, HER2− and Ki67 ≤ 30%), luminal B (ER+ and/or PR+, HER2− and 
Ki67 > 30% or ER+ and/or PR+ and HER2+), HER2 positive (ER− and PR− and HER2+) and triple‑negative (ER−, PR− 
and HER2−). RNA was extracted from formalin‑fixed paraffin‑embedded (FFPE) tissue, and miRNAs were successfully 
analyzed in 102 cancers and 36 benign controls using the 7th generation miRCURY LNA microarray containing probes 
targeting all human miRNAs as annotated in miRBASE version 19.0. Validation with RT‑qPCR was performed.
Results: On average, 450 miRNAs were detected in each sample, and 304 miRNAs were significantly different 
between malignant and benign tissue. Subgroup analyses of cancer cases revealed 23 miRNAs significantly dif‑
ferent between ER+ and ER− tumors, and 47 miRNAs different between tumors stratified according to grade. 
Significantly higher levels were found in high grade tumors for miR‑17‑5p (p = 0.006), miR‑20a‑5p (p = 0.007), miR‑
106b‑5p (p = 0.007), miR‑93‑5p (p = 0.007) and miR‑25‑3p (p = 0.015) from the paralogous clusters miR‑17‑92 and 
miR‑106b‑25. Expression of miR‑17‑5p (p = 0.0029), miR‑20a‑5p (p = 0.0021), miR‑92a‑3p (p = 0.011) and miR‑106b‑5p 
(p = 0.021) was significantly higher in triple‑negative tumors compared to the rest, and miR‑17‑5p and miR‑20a‑5p 
were significantly lower in luminal A tumors.
Conclusions: miRNA expression profiles were significantly different between malignant and benign tissue and 
between cancer subgroups according to ER− status, grade and molecular subtype. miRNAs in the miR‑17‑92 cluster 
and miR‑17 family were overexpressed in high grade and triple‑negative tumors associated with aggressive behavior. 
The expression and functional role of these miRNAs should be further studied in breast cancer to explore their poten‑
tial as biomarkers in diagnostic pathology and clinical oncology.
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Background
Breast cancer is a leading cause of cancer-related 
deaths. Annually, approximately 2.09 million women 
worldwide are diagnosed with breast cancer whereas an 
estimated 627.000 women die of the disease [1]. Breast 
cancer incidence has been increasing over the last dec-
ades in the Western world, also in Norway [2]. Mor-
tality rates are falling, leaving an increasing number 
of women alive with a history of the disease, but also 
exposed to risk of complications and side-effects due to 
treatment and with a life-long risk of relapse. There is a 
need for simple, safe and informative diagnostic tools 
to better identify the breast cancer tumors with the 
most aggressive behavior and to diagnose and treat the 
disease before distant metastases have been established 
and the disease is beyond curability.
MicroRNAs (miRNAs) are short single-stranded 
RNAs built up of 18-22 nucleotides after processing of 
the pri-miRNA by the nuclear RNase III protein Dro-
sha and sequentially cleavage of the hairpin-shaped 
precursor-miRNA by the RNase III Dicer in the cells’ 
cytoplasm [3]. MiRNAs are important regulators of 
gene expression at the post-transcriptional level, usu-
ally by either inhibiting translation or inducing mRNA 
degradation through incomplete or complete binding 
to a complementary sequence in the 3′ untranslated 
region (UTR) of their target mRNAs. It is well estab-
lished that miRNAs are involved in carcinogenesis, 
invasion and metastasis [4, 5] and display distinct pro-
files in cancer [6]. Further, miRNAs have properties 
that make them promising as biomarkers. They can be 
detected in blood, partly in extracellular vesicles known 
as exosomes, and in other body fluids such as urine and 
saliva [7, 8]. MiRNAs are very stable structures and can 
tolerate freezing and thawing [9]. Further, if miRNAs 
in blood could give information on the phenotype or 
aggressiveness of a given tumor, there is a possibility 
that easily obtained samples could give information on 
malignant disease, both at the time of primary diagno-
sis and in the metastatic setting [10].
The Norwegian Women and Cancer study (NOWAC) 
is a prospective study which started in 1991 and includes 
172,000 Norwegian women aged 30–70  years randomly 
sampled from the Norwegian Central Person Registry. 
The study is based on questionnaires with information on 
variables of importance to breast cancer risk such as life-
style, use of oral contraceptives, hormone replacement 
therapy, reproductive history and family history of breast 
cancer. From 2003 the study was expanded to include 
blood samples for whole-genome expression profiling 
(the NOWAC postgenome cohort) [11]. 49,633 samples 
of peripheral blood have been collected. Through link-
age to the Cancer Registry of Norway, women in the 
NOWAC postgenome cohort with a diagnosis of breast 
cancer have been identified.
The aim of this pilot study was to explore the miRNA 
expression profile in breast cancer tumors from the 
NOWAC postgenome cohort and to search for miRNAs 
that are significantly different in tumor tissue compared 
to benign breast tissue and could be detected in formalin-
fixed paraffin-embedded (FFPE) tissue, collected as part 
of routine diagnostics. Further, we wanted to identify 
miRNAs that are differently expressed in tumors with dif-
ferent aggressiveness and prognosis with special focus on 
high grad tumors and the triple-negative breast cancers.
Methods
Patient material and tumor classification
The 108 patients included in this pilot study were all par-
ticipants in the NOWAC postgenome cohort living in 
Northern Norway and diagnosed with breast cancer in 
the years 2004–2010. Diagnostic biopsies and breast can-
cer surgery were performed at the University Hospital 
of North Norway or the Nordland Central Hospital. As 
benign controls, FFPE tissues from 44 women undergo-
ing breast reduction surgery were included in the study. 
The controls were born in the same time period as the 
NOWAC participants (1943–1957) and underwent 
surgery in the same time period. Archived FFPE tis-
sue blocks were retrieved from the pathology labs at the 
University Hospital of North Norway and the Nordland 
Central Hospital together with the corresponding hema-
toxylin and eosin slides.
Histopathological data such as histological type, grade, 
size and lymph node status were collected from the origi-
nal pathology reports, but reevaluated and completed 
according to updated criteria by the breast pathologist in 
charge. Tumor grade was assessed based on gland forma-
tion, nuclear pleomorphism and mitotic count, based on 
the criteria modified by Elston and Ellis [12]. Immuno-
histochemical (IHC) analyses of estrogen receptor (ER), 
progesterone receptor (PR) and HER2 were performed 
on the needle biopsies from tumor taken at the time of 
diagnosis, as part of routine diagnostics. Cut-off value for 
ER positivity was ≥ 1% and for PR ≥ 10%. A HER2 IHC 
score of 3+ was considered positive, a score of 0–1+ 
negative whereas a score of 2+ would lead to further 
assessment of HER2 status by silver in situ hybridization 
(SISH). HER2 gene amplification was considered present 
if HER2/chromosome 17-ratio was > 2.2. IHC staining for 
the proliferation marker Ki67 was done on histological 
slides of tumor tissue from the primary surgery to dif-
ferentiate between luminal A and luminal B tumors. Ki67 
expression was evaluated in at least 500 tumor cells in the 
most proliferative active parts of tumor and reported as 
the percentage of positive tumor cell nuclei.
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The main molecular breast cancer subtypes were 
defined based on clinical grouping and immunohisto-
chemical staining of ER, PR, HER2 and Ki67 as recom-
mended by the St Gallen International Expert Consensus 
and previous publications [13, 14] as follows: luminal A 
(ER+ and/or PR+, HER2− and Ki67 ≤ 30%), luminal B 
(ER+ and/or PR+, HER2− and Ki67 > 30% or ER+ and/
or PR+ and HER2+), HER2 positive (ER− and PR− and 
HER2+) and triple-negative (ER−, PR− and HER2−). 
The term triple-negative cancer was preferred over basal-
like breast cancer since subgrouping was done as part of 
clinical, treatment-oriented classification and was based 
on receptor status alone. Most basal-like cancers are 
triple-negative, but triple-negative breast cancers are 
found to be genetically heterogeneous and are generally 
not considered synonymous with basal-like tumors [15], 
although considerable overlap has been demonstrated 
[16].
RNA extraction and microarray procedures
A trained pathologist selected the most representative 
tumor areas on histological slides and tissue cores from 
the corresponding areas of the FFPE blocks were col-
lected for extraction of total RNA using the Recover-
All Total Nucleic Acid Isolation kit (Life Technologies, 
Grand Island, NY, USA). Exiqon (Vedbaek, Denmark) 
performed the microarray hybridization and analyses as 
a bought service. In short, RNA quality and quantity was 
assessed using the NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE), and 250 ng 
total RNA from samples and reference was labeled with 
Hy3™ and Hy5™ fluorescent label (Exiqon, Vedbaek, 
Denmark), respectively, using the miRCURY LNA™ 
microRNA Hi-Power Labeling Kit (Exiqon, Vedbaek, 
Denmark). The Hy5™-labeled reference RNA contained 
an equal aliquot of all RNA species included in the study. 
The Hy3™-labeled samples and Hy5™-labeled reference 
RNA were mixed and hybridized to the 7th generation 
miRCURY LNA miRNA array (Exiqon) which contains 
capture probes targeting identified miRNAs in human, 
mouse, rat and their related viral sequences as anno-
tated in miRBASE. According to Exiqon, the array con-
tained 3100 capture probes covering 94% of the human 
miRNAs in miRBASE version 19.0. The hybridization 
was done using a Tecan HS4800 hybridization station 
(Tecan, Austria) and the microarray slides were stored 
in an ozone free environment after hybridization. The 
slides were scanned using the Agilent G2565BA Microar-
ray Scanner System (Agilent technologies Inc., USA) and 
the image analysis was carried out using the ImaGene 9.0 
software (BioDiscovery Inc., USA). The quantified signals 
were background corrected and normalized using quan-
tile normalization method. The detection threshold was 
calculated as 1.2 times the 25th percentile of the overall 
signal intensity of the individual slides. MiRNAs with 
intensities above threshold in < 20% of the samples were 
removed from the final dataset used for the expression 
analyses to ensure that the expression analyses were done 
on miRNAs which were expressed in enough samples 
to be of biological relevance [17]. However, all miRNAs, 
independently of the percentage of samples with detect-
able expression, were included in a screening analysis to 
explore if any one miRNA was uniquely expressed in any 
of the tumor subgroups.
RT‑qPCR validation
To validate the microarray miRNA analyses, RT-qPCR 
was performed by Exiqon on RNA purified from 40 of 
the tumor samples and 20 of the benign breast tissue 
controls included in the study. Due to the clinical rel-
evance of the molecular subtypes and the scientific focus 
on the triple-negative breast cancers, the tumor samples 
were randomly selected within each molecular subtype 
so that there would be about ten cases in each subgroup. 
15 of the miRNAs from the microarray analysis were 
selected for validation. PCR-validation was done after the 
initial statistical analyses on the miRNA expression levels 
from the microarray had been performed. MiRNAs with 
highly significant differences between tissue types and/or 
tumors subgroups according to tumor grade and recep-
tor status with special focus on the triple-negative breast 
cancers, were selected for validation. Associated miR-
NAs, such as miRNA clusters, -family or -strands from 
a common precursor with a coordinated regulation of 
expression were given priority over individual miRNAs. 
However, four single miRNAs of potential interest for 
future studies were also included, based on known bio-
logical functions or potential for novel findings, based 
on the microarray. The following miRNAs were analyzed 
using PCR: the let-7 family members let-7b-5p and let-7c, 
the two miR-126-strands miR-126-5p and miR-126-3p, 
the miR-143-145 cluster members miR-143-3p and 
miR-145-5p, and the miR-17-92 cluster/miR-17-family 
members miR-17-5p, miR-20a-5p, miR-92a-3p, miR-
106b-5p and miR-93-5p. In addition, the well described 
miR-155-5p and miR-146a-5p were included in the PCR-
analyses. Finally, the less known miRNAs miR-3182 and 
miR-3164 were included in the PCR-analyses for explora-
tory purposes. The design of the study and a schematic 
overview of the analyses done is presented in Fig. 1.
In short, the Qiagen miRNeasy FFPE kit was used to 
extract RNA from FFPE tissue cores according to the 
manufacturer’s instructions (Qiagen, Hilden, Germany). 
10 ng RNA was reverse transcriped using the miRCURY 
LNA Universal RT microRNA PCR, Polyadenylation and 
cDNA synthesis kit (Exiqon) before PCR-reactions were 
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performed on 100× diluted cDNA using ExiLENT SYBR 
Green master mix. The amplification was done in 384 
well plates in a Light Cycler 480 Real-Time PCR System 
(Roche, Basel, Switzerland) where all reverse transcrip-
tion reactions were done in duplicates. The Normfinder 
software was used by Exiqon to find the most suitable 
reference miRNAs based on stable expression across the 
data set. Of the suitable reference miRNAs, miR-664a-3p 
was detected in all samples in concentrations comparable 
to the target miRNAs and could be used for normaliza-
tion. Normalized expression values for each miRNA were 
calculated based on the PCR quantification cycle (Cq) 
and the average of the normalizer detected in all samples 
using the formula: normalized Cq = average Cq (all sam-
ples) − assay Cq (sample).
Statistics
The miRNA microarray and PCR expression data were 
analysed using the Linear Models for Microarray and 
RNA-Seq Data (Limma) package in R. Moderated F-sta-
tistics were applied. p-values were corrected for multiple 
testing by controlling the false discovery rate using the 
method of Benjamini & Hochberg. Descriptive statis-
tics, non-parametric tests and correlation analysis, using 
Pearson correlation, were performed using Stata, version 
14 (StataCorp LLC, Texas, USA).
Results
Patient and tumor characteristics
The women included in the NOWAC study are all 
born in the period 1943–1957. The mean age at breast 
cancer diagnosis in our study was 57.6  years (range 
47–65  years) whereas the benign breast tissue con-
trols were collected from women with a mean age at 
surgery of 57.4  years (range 47–66  years). Of the 108 
breast cancer tumors, 81 tumors (75%) were hormone 
receptor positive, 20 tumors (18.5%) were HER2 posi-
tive of which 11 tumors (10.2%) were triple-positive 
(ER+, PR+, HER2+), and 16 cases (14.8%) had triple-
negative tumors. 28 of the tumors (25.9%) had histo-
logic characteristics of aggressive breast cancer with 
low differentiation, cellular atypia and high mitotic 
activity, corresponding to histologic grade 3. Molecu-
lar subclassification of tumors, based on surrogate 
miRNA expression in tissue in the NOWAC study
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Fig. 1 Study schema for the analyses of miRNA expression in tissues. The schema illustrates the work flow, the statistical analyses and the subgroup 
analyses performed on data from miRNA microarray and PCR in the study
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markers, demonstrated 80 tumors (74.1%) to be of the 
luminal type, whereas 9 (8.3%) and 16 tumors (14.8%) 
ended up as HER2 positive and triple-negative, respec-
tively. The patient material and tumor characteristics 
are presented in Table 1.
MiRNA expression levels in malignant versus normal breast 
tissue
Of a total of 108 cases of invasive breast cancer cases in 
this pilot study, five specimens did not have satisfactory 
RNA quality and were not included in the microarray, 
and one specimen was identified as an extreme outlier 
in the unsupervised analyses of the miRNA results using 
Table 1 Patient characteristics and clinicopathological variables for the study population and samples included in PCR 
validation
Characteristic NOWAC pilot study
Study population PCR analyses
Cases N (%) Controls N (%) Cases N (%) Controls N (%)
Study subjects 108 (100) 44 (100) 40 (100) 20 (100)
Age (years)
 ≤ 50 7 (6.5) 1 (2.3) 1 (2.5) 1 (5.0)
 > 50 101 (93.5) 43 (97.7) 39 (97.5) 19 (95.0)
Tumor grade
 1 34 (31.5) – 7 (17.5) –
 2 42 (38.9) – 17 (42.5) –
 3 28 (25.9) – 16 (40.0) –
 Unknown 4 (3.7) 0 (0)
Tumor size (mm)
 0–10 23 (21.3) – 2 (5.0) –
 10–20 50 (46.3) – 24 (60.0) –
 > 20 34 (31.5) – 14 (35.0) –
 Unknown 1 (0.9) 0 (0)
Lymph node status
 N0 73 (67.6) – 30 (75.0) –
 N+ 34 (31.5) – 10 (25.0) –
 Unknown 1 (0.9) – 0 (0) –
Hormone receptor status
 ER/PR positive 81 (75.0) – 23 (57.5) –
 ER/PR negative 27 (25.0) – 17 (42.5) –
 Unknown 0 (0) – 0 (0) –
HER2 receptor status
 HER2 positive 20 (18.5) – 15 (37.5) –
 HER2 negative 86 (79.6) – 25 (62.5) –
 Unknown 2 (1.9) – 0 (0) –
Molecular subtype
 Luminal A 58 (53.7) – 12 (30.0) –
 Luminal B 22 (20.4) – 11 (27.5) –
 HER2 positive 9 (8.3) – 7 (17.5) –
 Triple‑negative 16 (14.8) – 10 (25.0) –
 Unknown 3 (2.8) 0 (0)
Histological type
 Infiltrating carcinoma NST 92 (85.2) – 35 (87.5) –
 Lobular carcinoma 10 (9.3) – 3 (7.5) –
 Tubular 3 (2.8) – 0 (0) –
 Other 3 (2.8) – 2 (5.0) –
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principal component analysis (PCA), leaving 102 breast 
cancer specimens for final analysis. Six of the 44 benign 
breast surgery specimens had RNA quality of unsatisfac-
tory quality and two benign tissue controls were identi-
fied as outliers after unsupervised microarray analysis, 
resulting in 36 benign tissue controls in the final statisti-
cal analyses.
Screening analyses of all detected probes did not dem-
onstrate any miRNAs that were uniquely expressed in 
any of the tissue types or breast cancer subgroups. For 
further expression analyses, 1558 probes were discarded 
due to intensities above threshold in less than 20% of 
the samples. Noteworthy, the samples contained simi-
lar levels of detectable miRNAs indicating comparable 
sample quality. On average, 450 different miRNAs were 
detected above threshold in each sample. 304 miRNAs 
demonstrated significantly different expression levels in 
tumor tissue compared to normal tissue. Heat map and 
PCA demonstrated that the miRNAs in normal tissue 
and tumor samples clustered according to their biologi-
cal group (Fig. 2). This indicates that differences between 
the groups are the largest contributors to variation in 
miRNA expression and underlines that the miRNA pro-
file in malignant and benign breast tissue is significantly 
different.
Scatterplots of the 20 most significantly differently 
expressed miRNAs in malignant breast tumors compared 
to benign breast tissue, based on p-values, are shown 
in Fig. 3. Noteworthy, of these 20 miRNAs, 18 miRNAs 
were downregulated in cancer compared to benign breast 
tissue.
Further, the calculated log fold change (logFC) between 
malignant and benign tissue adds information on the 
probable biological relevance of the observed difference 
in miRNA expression. The 20 most upregulated and the 
20 most downregulated miRNAs in cancer, based on the 
logFC-values, are listed in Table 2.
MiRNA expression levels according to breast cancer 
subtypes
The expression of miRNAs in breast cancer strati-
fied according to receptor expression, histologic grade, 
molecular subtype, tumor size and lymph node status 
was explored, using moderated F-statistics and the Ben-
jamini & Hochberg correction for multiple comparisons 
on microarray miRNA expression data. The analysis 
revealed that 23 of the detected miRNAs were signifi-
cantly different between ER+ and ER− tumors (Table 3 
and Fig. 4).
A total of 47 miRNAs demonstrated significantly dif-
ferent expression between tumors stratified according 
to histologic grade. Noteworthy, among the six miRNAs 
with the most significantly different expression according 
to grade, two miRNAs in the miR-17-92 cluster and two 
miRNAs in the paralogue miR-106b-25 cluster were rep-
resented: miR-17-5p (p = 0.006), miR-20a-5p (p = 0.007), 
miR-106b-5p (p = 0.007), and miR-93-5p (p = 0.007). 
Also the cluster members miR-25-3p and miR-92a-3p 
demonstrated significantly different expression accord-
ing to grade. Subgroup analyses with contrast tests dem-
onstrated that all of these miRNAs in the miR-17-92 and 
miR-106b-25 clusters were significantly higher expressed 
in high grade tumors (Table 4 and Fig. 5a, b).
The statistical results when analyzing miRNA expres-
sion in high grade tumors, indicated that the miR-17-
92 and miR-106b-25 clusters were highly interesting. 
Further, the triple-negative tumors are of special clini-
cal interest due to their aggressive behavior and lack of 
specific, targeted treatment. When comparing miRNA 
expression in these tumors compared to the rest, the 
expression of miR-17-5p (p = 0.0029), miR-20a-5p 
(p = 0.0021), miR-92a-3p (p = 0.011) and miR-106b-5p 
(p = 0.021) was significantly higher in triple-negative 
breast cancers (Table 5).
Further, overall and contrast tests comparing the 
miRNA levels in individual molecular subgroups with 
correction for multiple comparisons were performed. 
We found that miR-17-5p and miR-20a-5p were signifi-
cantly different between luminal A and triple-negative 
tumors (p = 0.001 for both miRNAs), borderline signifi-
cant between luminal A and luminal B cancers for both 
miR-17-5p and miR-20a-5p with FDR-adjusted p-values 
of 0.06 and 0.07, respectively, but not between any of the 
other molecular subgroups or for any of the other miR-
NAs in the miR-17-92 and miR-106b-5p clusters (Fig. 6). 
Further, both miR-17-5p (p = 0.0030) and miR-20a-5p 
(p = 0.0029) were lower in luminal A tumors compared to 
the rest.
The expression of 209 miRNAs was significantly differ-
ent in tumors according to size, using 20 mm in diameter 
Fig. 2 Heat map and principal component analysis of miRNAs with greatest variability between cases and controls. a Heat map diagram with 
unsupervised hierarchical clustering is presented for all samples and the top 50 miRNAs with the largest variation across all samples. Each row 
represents a miRNA and each column represents a sample. The color scale illustrates the relative expression level of a miRNA across all samples: 
red color represents an expression level below the mean, green color expression above the mean. b Plot of the principal component analysis 
performed on all samples and on the 50 miRNAs with the largest variation across all samples. The normalized log‑transformed Hy3 values have 
been used for the analysis
(See figure on next page.)
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Fig. 3 The 20 most differently expressed miRNAs in breast cancer and benign tissue, based on p‑values. The scatterplots show the expression of the 
miRNAs in 36 benign tissue controls and 102 breast cancer tumors analyzed by microarray. Mean, standard deviation and false discovery rate (FDR) 
adjusted p‑values are presented. E indicates exponential number
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as cutoff (Additional file 1: Table S1). Finally, there were 
no significant differences in expression of any miRNA 
in tumors stratified according to HER2 status or lymph 
node metastasis.
PCR validation
14 of the 15 miRNAs selected for PCR validation were 
successfully quantitated in FFPE tissue, using qPCR 
(Fig.  7 and Table  6). The previously functionally unde-
scribed miR-3164 was significantly differently expressed 
in benign versus malignant breast tissue using microar-
ray. However, miR-3164 was only detectable and in very 
low expression levels in four tumor samples by PCR, 
which could be due to very low expression levels or sub-
optimal probes, and was therefore not included in further 
analyses.
PCR analyses validated the results from the microarray 
experiment. Let-7b-5p, miR-146a-5p, miR-3182, let-7c 
and miR-155-5p were among the miRNAs demonstrat-
ing significantly different expression according to ER sta-
tus in the microarray. Comparison between ER positive 
and ER negative cancers as measured by PCR, validated 
the results, demonstrating a logFC of 0.87 for let-7b-5p 
(p = 0.029), logFC − 1.57 for miR-146a-5p (p = 0.00014), 
logFC − 0.99 for miR-3182 (p = 0.028), logFC 0.88 for 
let-7c (p = 0.029) and a logFC of − 1.64 for miR-155-5p 
(p = 0.00012). Higher levels of the miR-17-92 cluster 
members were detected in high grade tumors with signif-
icant difference between miR-17-5p expression in grade 
1 and grade 3 tumors (Fig. 5c). As for microarray, PCR-
analyses found significantly higher levels of miR-17-5p 
(p = 0.0025), miR-20a-5p (p = 0.0053) and miR-92a-3p 
(p = 0.0073) in triple-negative breast cancers compared 
to the rest, and the miRNA expression levels tended to be 
lower in luminal A tumors compared to others, although 
the adjusted p-values were not significant (Table  7). 
Importantly, Pearson correlation coefficient demon-
strated strong and significant correlations between 
the microarray and qPCR data for all the 14 detectable 
miRNAs. Scatterplots comparing microarray and PCR 
expression levels for the analyzed miR-17-92 and miR-
106b-25 cluster members are presented in Fig. 8.
Discussion
This study has explored the miRNA expression profile 
in breast cancer in the NOWAC study. The distribution 
of tumor characteristics such as receptor status, histo-
logic grade and molecular subtype is as expected based 
on findings in larger epidemiological studies and the col-
lected national data in the Norwegian Cancer Registry, 
again underlining that the NOWAC study population is 
a representative cohort of the Norwegian female popula-
tion in this age-group [18].
Table 2 The most up- and  downregulated miRNAs 
in cancer compared to benign tissue, sorted by logFC
Log fold change (logFC) values are calculated, based on the log2 transformed 
intensity values (Hy3) by microarray analyses, comparing breast cancer 
to benign tissue controls. The 20 most upregulated and the 20 most 
downregulated miRNAs, sorted by highest and lowest logFC, respectively, are 
presented
* False discovery rate (FDR) adjusted p-value. E indicates exponential number























miR‑451a − 2.647 1.89E−18
miR‑143‑3p − 2.096 4.90E−27
miR‑99a‑5p − 2.093 3.52E−24
miR‑4328 − 2.090 1.42E−27
miR‑145‑5p − 2.061 3.39E−29
miR‑205‑5p − 2.027 1.45E−12
miR‑195‑5p − 2.023 8.11E−25
miR‑125b‑5p − 1.970 8.70E−14
miR‑126‑3p − 1.862 1.89E−25
miR‑26b‑5p − 1.837 1.01E−24
miR‑4324 − 1.651 1.04E−25
miR‑29a‑3p − 1.592 3.44E−12
miR‑10b‑5p − 1.483 6.87E−24
miR‑30b‑5p − 1.452 1.03E−15
let‑7d‑5p − 1.450 6.25E−21
miR‑130a‑3p − 1.406 4.80E−19
miR‑199b‑5p − 1.400 1.84E−23
miR‑29b‑3p − 1.339 1.56E−14
miR‑199a‑3p − 1.316 2.13E−13
miR‑24‑3p − 1.287 7.37E−18
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Noteworthy, we found the miRNA expression profile to 
be significantly different in benign and malignant breast 
tissue, as illustrated by the principal component analy-
sis. Of the 20 most differentially expressed miRNAs in 
microarray, presented in Fig. 3, only two miRNAs dem-
onstrated higher expression levels whereas 18 miRNAs 
demonstrated lower expression levels in tumor compared 
to benign breast tissue. Of 14 miRNAs quantitated by 
PCR, 12 miRNAs were significantly differently expressed 
in breast cancer and benign tissue, of which seven miR-
NAs had significantly lower expression in breast cancer 
tissue. Tumors have often been found to have reduced 
levels of mature miRNA which could be explained by 
defects in their biogenesis, for instance through loss of 
key proteins in their synthesis such as DICER, epigenetic 
silencing through mechanisms such as promoter hyper-
methylation and/or genetic loss of miRNA loci [5, 19].
Among the most differentially expressed miRNAs, 
we found downregulation in tumor tissue of miR-
NAs such as miR-143-3p and miR-145-5p in the miR-
143/145 cluster, miR-10b-5p, miR-99a and let-7a-2-3p 
which is in line with other studies comparing malignant 
and benign breast tissue [20–25]. Among the 20 most 
deregulated miRNAs, we observed significantly higher 
levels of miR-4419b and miR-2964a-5p. MiR-4419b 
has been found to be upregulated in small cell tumors 
of the esophagus with rapid relapse after surgery [26] 
and miR-2964a in pancreatobiliary adenocarcinoma 
[27], but they are not functionally described in breast 
cancer. However, as established by miRNA profiling 
across cancer types, many of the deregulated miRNAs 
are common in different malignancies.
Analyses of the breast cancer cases revealed sig-
nificant differences between cancer subtypes. ER is of 
special interest in breast cancer as a prognostic and 
predictive marker, and we found 23 miRNAs to be 
significantly different according to ER status. Among 
these, miR-155 has previously been shown to be upreg-
ulated in breast cancer compared to normal tissue and 
upregulated in ER− compared to ER+ tumors [22, 24, 
28], as verified in our study. Noteworthy, miR-342-3p, 
which we found to be most significantly different with 
higher expression in ER+ compared to ER− tumors, 
has also been found by others to be strongly associated 
Table 3 MiRNAs demonstrating significantly different expression according to estrogen receptor status
Expression levels are given as the mean with standard deviation (SD) of log2 transformed intensity values (Hy3) by microarray analyses
* False discovery rate (FDR) adjusted p-value. E indicates exponential number
miRNA ER positive breast cancer ER negative breast cancer logFC p*
Mean SD Mean SD
miR‑342‑3p 7.60 0.79 6.72 0.51 0.881 2.29E−4
let‑7b‑5p 10.36 0.79 9.48 0.64 0.878 2.76E−4
miR‑125a‑3p 9.01 0.46 8.50 0.42 0.514 2.76E−4
miR‑146a‑5p 6.04 0.40 6.60 0.74 − 0.561 5.16E−4
miR‑3182 9.74 0.82 10.64 0.92 − 0.900 7.20E−4
miR‑146b‑5p 6.59 0.36 7.03 0.56 − 0.442 9.16E−4
miR‑222‑3p 6.97 0.40 7.43 0.63 − 0.464 0.0021
miR‑142‑3p 6.85 0.48 7.39 0.76 − 0.540 0.0030
let‑7c 8.36 0.67 7.79 0.41 0.564 0.0045
miR‑342‑5p 6.67 0.42 6.30 0.33 0.365 0.0048
miR‑155‑5p 7.28 0.24 7.53 0.40 − 0.251 0.011
miR‑let‑7a‑5p 9.28 0.79 8.68 0.49 0.595 0.017
miR‑920 7.05 0.22 7.22 0.19 − 0.171 0.018
miR‑214‑3p 8.33 0.42 8.00 0.41 0.337 0.018
miR‑223‑5p 6.35 0.38 6.68 0.50 − 0.332 0.020
miR‑574‑3p 7.50 0.19 7.34 0.21 0.154 0.027
miR‑3135a 6.42 0.14 6.54 0.22 − 0.126 0.033
miR‑20a‑5p 6.58 0.42 7.00 0.86 − 0.420 0.040
miR‑221‑3p 6.64 0.26 6.87 0.41 − 0.223 0.042
miR‑665 9.15 0.52 9.56 0.68 − 0.410 0.042
miR‑4758‑3p 6.60 0.29 6.81 0.28 − 0.205 0.044
miR‑4419b 11.28 0.28 11.47 0.24 − 0.195 0.044
miR‑4436b‑3p 6.85 0.32 7.07 0.26 − 0.219 0.044
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with ER+ status and to predict ER+ receptor status 
[29, 30].
Interestingly, when using an agnostic approach and 
exploring the miRNA expression profile in breast cancer 
tissue in an epidemiological study using microarray, four 
of the six miRNAs found to be most significantly differ-
ent between tumors of different grade, were miR-17-5p, 
miR-20a-5p, miR-106b-5p and miR-93-5p, belonging to 
the miR-17-92 cluster and its paralogue miR-106b-25, 
and all members of the miR-17 family. Further analyses 
demonstrated that these miRNAs were significantly 
higher in tumors with high histologic grade and triple-
negative status. Other studies have also found higher 
levels of miRNAs in these clusters in the most aggres-
sive breast cancers using fresh-frozen tumor tissue and a 
bead-based flow cytometric miRNA expression method, 
analyzing on a smaller number of miRNAs than in our 
study [28]. Calvano Filho et  al. found higher levels of 
miRNAs in the miR-17-92 cluster and miR-17 family in 
selected triple-negative tumors compared to luminal A 
Fig. 4 MiRNAs demonstrating significantly different expression according to estrogen receptor status. The scatterplots show the expression of 
miRNAs in estrogen receptor positive and estrogen receptor negative breast cancers. Mean, standard deviation and false discovery rate (FDR) 
adjusted p‑values are presented
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breast cancers, using RT-PCR [31]. MiR-18a and -18b 
have been shown to have higher expression levels in ER− 
compared to ER+ tumors, and to directly target ERα [32].
Of note, when comparing the clustered miRNAs’ 
expression in breast cancer to benign tissue, we found 
significantly higher expression of miR-106b-5p and miR-
93-5p in breast cancer tissue compared to benign tissue 
using PCR; by using microarray we found no significant 
differences. Higher levels of miR-17 family members such 
as miR-93, miR-25 and miR-106b in cancer have also 
been demonstrated in other studies using deep sequenc-
ing, microarray and/or PCR [33–35]. Several of these 
studies were smaller than ours and used tissue adjacent 
to the breast tumor as benign tissue controls. As in our 
study, using microarray, others have also found members 
of the miR-17-92 cluster and miR-17 family such as miR-
17-5p, miR-20a-5p and miR-92a-3p to be downregulated 
in solid cancers compared to benign tissue [19, 24]. We 
could, however, only validate this result for miR-92a-3p 
using PCR; for miR-17-5p and miR-20a-5p no significant 
difference was observed. Noteworthy, in the PCR-assays, 
a relative larger proportion of the cancers was triple-
negative compared to the entire study cohort included 
in the microarray, underlining that differences between 
breast cancer subgroups could influence comparisons 
between cancer and benign tissue. Although our study 
includes more tumor and benign tissue samples com-
pared to many other studies, our study material is still 
small, and the results must be interpreted with caution. 
Further, when performing expression analyses on tissue, 
Table 4 Expression of miRNAs in the miR-17-92 and miR-106b-25 clusters according to histologic grade
Expression levels are given as the mean (standard deviation) of log2 transformed intensity values (Hy3) by microarray analyses
* False discovery rate (FDR) adjusted p-value. E indicates exponential number
MiRNA Tissue Grade n Mean (SD) Contrasts p*
miR‑17‑5p Benign – 36 6.67 (0.68)
Cancer All 102 6.32 (0.66) Cancer vs benign 0.014
Cancer 1 32 6.10 (0.45) Grade 1 vs 2 and 3 0.0040
Cancer 2 41 6.16 (0.48) Grade 1 and 2 vs 3 2.45E−5
Cancer 3 27 6.82 (0.85) Grade 1 vs 3 6.84E−5
miR‑20a‑5p Benign – 36 7.34 (0.74)
Cancer All 102 6.69 (0.60) Cancer vs benign 1.23E−6
Cancer 1 32 6.54 (0.38) Grade 1 vs 2 and 3 0.014
Cancer 2 41 6.52 (0.39) Grade 1 and 2 vs 3 2.45E−5
Cancer 3 27 7.14 (0.82) Grade 1 vs 3 8.50E−5
miR‑92a‑3p Benign – 36 7.79 (0.62)
Cancer All 102 7.23 (0.52) Cancer vs benign 1.23E−6
Cancer 1 32 7.19 (0.47) Grade 1 vs 2 and 3 0.27
Cancer 2 41 7.06 (0.42) Grade 1 and 2 vs 3 0.00037
Cancer 3 27 7.55 (0.59) Grade 1 vs 3 0.0068
miR‑106b‑5p Benign – 36 6.68 (0.59)
Cancer All 102 6.56 (0.51) Cancer vs benign 0.24
Cancer 1 32 6.36 (0.38) Grade 1 vs 2 and 3 0.0019
Cancer 2 41 6.49 (0.44) Grade 1 and 2 vs 3 6.84E−5
Cancer 3 27 6.91 (0.61) Grade 1 vs 3 6.84E−5
miR‑93‑5p Benign – 36 6.81 (0.41)
Cancer All 102 7.00 (0.56) Cancer vs benign 0.095
Cancer 1 32 6.80 (0.39) Grade 1 vs 2 and 3 0.0032
Cancer 2 41 6.92 (0.47) Grade 1 and 2 vs 3 6.84E−5
Cancer 3 27 7.39 (0.69) Grade 1 vs 3 8.50E−5
miR‑25‑3p Benign – 36 6.63 (0.33)
Cancer All 102 6.54 (0.33) Cancer vs benign 0.19
Cancer 1 32 6.44 (0.23) Grade 1 vs 2 and 3 0.013
Cancer 2 41 6.48 (0.28) Grade 1 and 2 vs 3 0.00016
Cancer 3 27 6.75 (0.41) Grade 1 vs 3 0.00043
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Fig. 5 Expression levels of miRNAs in the miR‑17‑92 and miR‑106b‑25 clusters according to histologic grade. a Scatterplots show the expression 
of miRNAs in breast cancer cases according to their histologic grade: grade 1 (G1), grade 2 (G2) or grade 3 (G3). Means and standard deviations 
from microarray analyses are presented. p‑values for comparisons are presented in b. b MiRNA expression in breast cancer cases and in benign 
tissue controls is presented with microarray expression levels given as mean (standard deviation) of log2 transformed Hy3 intensity values. 
*False discovery rate (FDR) adjusted p‑value < 0.05, **p‑value < 0.01. c MiRNA expression in breast cancers and in benign tissue analyzed by qPCR. 
Expression levels are presented as mean (standard deviation) of normalized PCR quantification cycle (Cq) values based on the average of the 
normalizer assay detected in all samples and the formula: normalized Cq = average Cq (all samples) − assay Cq (sample). Negative PCR expression 
values indicate lower expression levels compared to the normalizer. *False discovery rate (FDR) adjusted p‑value < 0.05, **p‑value < 0.01
Table 5 Expression of  the  miR-17-92 cluster and  paralogues in  triple-negative tumors compared to  others, using 
microarray
Expression levels are given as the mean (standard deviation) of log2 transformed intensity values (Hy3) by microarray analyses
* False discovery rate (FDR) adjusted p-value
MiRNA Triple‑negative tumors Not triple‑negative tumors logFC p*
Mean SD Mean SD
miR‑17‑5p 6.80 1.10 6.22 0.50 0.581 0.0029
miR‑20a‑5p 7.16 1.05 6.60 0.42 0.566 0.0021
miR‑92a‑3p 7.55 0.75 7.17 0.44 0.384 0.011
miR‑106b‑5p 6.84 0.72 6.50 0.45 0.341 0.021
miR‑93‑5p 7.23 0.76 6.96 0.51 0.270 0.094
miR‑25‑3p 6.66 0.41 6.51 0.31 0.147 0.10
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one must be aware that the tissue cores contain other 
cellular elements contributing to the RNA pool such as 
immune cells, endothelial cells and fibroblasts, where 
malignant tissue would be expected to be more hetero-
genic compared to benign tissue. Hence, differences in 
miRNA expression between malignant and benign tissue 
could also, in part, be attributed to differences in tissue 
composition where tumor heterogeneity could influence 
the results [36].
Still, our results from breast cancer subgroup analyses, 
using both microarray and PCR, point to the miR-17-92 
cluster and miR-17-family as overexpressed in aggres-
sive breast tumors. The miR-17-92-cluster is located on 
chromosome 13 in the locus of the non-protein cod-
ing gene MIR17HG (miR-17-92 cluster host gene) and 
was first identified as the gene “chromosome 13 open 
reading frame 25” (C13orf25) found to be amplified in 
human B-cell lymphoma [37]. The cluster is transcribed 
as a polycistronic primary transcript that give rise to six 
mature miRNAs: miR-17, miR-18a, miR-19a, miR-19b, 
miR-20a, and miR-92a-1 [38, 39]. Transcriptional regula-
tion of C13orf25 can be part of the molecular basis for the 
coordinated expression of cluster members as observed 
in our study. A correlation in expression of the individual 
miRNAs in the miR-17-92 cluster [29] and also correla-
tion of expression of the miR-106b-25 cluster members 
and their host gene MCM7 on chromosome 7 has been 
shown [28]. The miR-17-92 cluster has been shown to 
be regulated by the transcription factor and proto-onco-
gene MYC which binds to the promoter region directly 
upstream of the miR-17 locus [40]. The cluster is highly 
expressed in a range of hematopoietic malignancies 
including MYC-rearranged Burkitt’s lymphomas [41]. 
High MYC-activation is also found in triple-negative 
breast tumors [42, 43] which could partly explain our 
findings of high miR-17-92-expression in triple-negative 
cancers. Similarly, the miR-17-92 promoter has bind-
ing sites for HES1 [39], a transcriptional repressor in 
the Notch signaling pathway which is overexpressed in 
triple-negative breast cancer [44]. N-myc has also been 
found to induce miR-17-92 expression in medulloblas-
tomas [45]. NDRG2, N-myc downstream-regulated 
gene 2, has been found to be significantly higher in tri-
ple-negative breast cancers compared to other subtypes 
[46], again indicating that differences in expression and 
activity of transcription factors targeting the miR-17-92 
promoter vary between breast cancer subtypes and can 
explain differences in miR-17-92 expression.
However, we also observed significant changes in the 
expression of miRNAs that are members of the paralogue 
cluster miR-106b-25 on chromosome 7 comprising miR-


































Fig. 6 Expression levels of miRNAs in the miR‑17‑92 and miR‑106b‑25 clusters according to molecular subtype. MiRNA expression in breast cancer 
and benign tissue is presented with microarray expression levels given as mean (standard error) of log2 transformed intensity values (Hy3). *False 
discovery rate (FDR) adjusted p‑value < 0.05, **p‑value < 0.01
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its host gene, MCM7, as well as miR-20a in the miR-17-
92 cluster, are induced by the transcription factors E2F1 
and E2F3 which are regulated by MYC [47–49]. The clus-
ter has also been shown to be regulated by bromodomain 
protein 4 (BRD4) which is increased in MYC-driven can-
cers [50]. Similar to the miR-17-92-cluster, miR-106b-25 
is transcriptionally regulated by N-myc [51]. Of note, the 
expression of the miRNAs in the clusters is also regulated 
by mechanisms such as epigenetic modifications induced 
by hypoxia [52], independent transcription of pri-miR-
NAs from an alternative promoter, alternative splicing 
[53], and post-transcriptional modifications of the long 
primary transcripts based on their tertiary structure [54, 
55]. These mechanisms allow for differential expression 
of the individual miRNAs within the clusters and miRNA 
families. Further, differences in expression of DICER1, 
AGO and DROSHA, all crucial to miRNA biosynthe-
sis, between breast cancer subtypes have been shown 
[28]. Summarized, the paralogous clusters seem to have 
important transcription factors and regulatory pathways 
in common. Indeed, it has been shown that the clusters 
are evolutionary conserved and it is suggested that they 
derive from a single gene that underwent duplication, 
mutations and losses of individual miRNAs [56, 57].
Further, clustered miRNAs seem to cooperate by regu-
lating similar sets of genes belonging to specific signal-
ing pathways [58] which fits with the sequence homology 
and conserved seed sequences of the miRNA within 
the clusters [59]. The miR-17 family of miRNAs share 
the same seed sequence of special importance for bind-
ing and targeting mRNAs, and include miR-17-5p, miR-
20a-5p, miR-20b-5p, miR-106a-5p, miR-106b-5p and 
miR-93-5p from clusters miR-17-92, 106b-25 and the 
third paralogue cluster miR-106a-363 [38]. Of the three 
paralogues, involving four miRNA families, the miR-17-
92 cluster is best described. MiR-17 and miR-19a have 
been shown to target mitogen activated kinases (MAPKs) 
such as extracellular signal-regulated kinase (ERK) 
1/2, and key signaling molecules in the MAPK signal-
ing pathway such as KRAS and RAF1 [60]. The MAPK 
signaling pathways regulate cellular proliferation, migra-
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Fig. 7 Heat map diagram with two‑way hierarchical clustering of miRNAs and samples analyzed by PCR. Each row in the diagram represents one 
miRNA, and each column represents one sample. The miRNA clustering tree is shown on the left. The color scale illustrates the relative expression 
level of a miRNA across all samples with red color indicating expression level above the mean, green color expression lower than the mean
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in many cancers, including breast cancer [61]. Note that 
both miR-17 and miR-20a have been shown to target 
E2F1, thereby taking part in a negative feed-back loop 
where the E2F transcription factors induce transcrip-
tion of miRNAs that have the same transcription factors 
as their target [40, 49]. In addition, miR-17 and miR-20a 
targets the type II transforming growth factor β (TGF-
β) receptor II whereas miR-18a targets Smad 4 down-
stream in the TGF-β signaling pathway, thereby opposing 
the tumor-suppressive effects of TGF-β and promoting 
angiogenesis [62]. Interestingly, miR-17-92 has also been 
found to target the cyclin-dependent kinase inhibitor p21 
and the apoptosis facilitator BCL2L11 which are media-
tors of TGF-β effects on proliferation and apoptosis [57]. 
Noteworthy, BCL2L11 is also targeted by miR-106b-25, 
again underlining how the miRNA clusters share targets 
[63]. MiR-17-5p has been shown in cellular assays to play 
an important role in cancer cell invasion and migration 
by suppressing HBP1 and consequently Wnt/β-catenin 
[64]. The miR-17-92 cluster members can also suppress 
the specificity protein (Sp) repressor ZBTB4, which in 
turn facilitates upregulation of Sp transcription factors 
and their target genes, thereby displaying tumor pro-
moting functions [65]. MiR-19 has been shown to excert 
Table 6 MiRNA expression in  breast cancer and  benign 
breast tissue, measured by PCR
Expression levels are presented as mean (standard deviation) of normalized 
PCR quantification cycle (Cq) values based on the average of the normalizer 
assay detected in all samples and the formula: normalized Cq = average Cq (all 
samples) − assay Cq (sample). Negative PCR expression values indicate lower 
expression levels compared to the normalizer
* False discovery rate (FDR) adjusted p-value. E indicates exponential number
miRNA Breast cancer Benign tissue logFC p*
Mean ± SD Mean ± SD
let‑7b‑5p 3.41 ± 1.11 4.28 ± 1.05 − 0.87 0.0094
let‑7c 2.54 ± 0.99 3.84 ± 0.90 − 1.30 4.76E−5
miR‑126‑3p 2.98 ± 1.04 4.24 ± 0.79 − 1.26 5.42E−5
miR‑126‑5p − 2.05 ± 1.00 − 0.86 ± 0.80 − 1.18 6.19E−5
miR‑143‑3p 2.84 ± 1.16 4.18 ± 0.81 − 1.35 6.19E−5
miR‑145‑5p 3.31 ± 1.53 5.98 ± 0.69 − 2.67 1.79E−8
miR‑155‑5p − 0.54 ± 1.37 − 2.23 ± 1.11 1.69 5.04E−5
miR‑146a‑5p − 0.48 ± 1.36 − 1.22 ± 1.08 0.74 0.048
miR‑3182 − 7.24 ± 1.71 − 9.17 ± 1.43 1.93 0.028
miR‑17‑5p − 4.70 ± 1.45 − 4.92 ± 1.11 0.22 0.60
miR‑20a‑5p 2.36 ± 1.18 2.29 ± 0.67 0.069 0.81
miR‑92a‑3p 1.96 ± 1.03 2.60 ± 0.76 − 0.65 0.025
miR‑106b‑5p 0.45 ± 1.03 − 0.84 ± 0.61 1.29 3.81E−5
miR‑93‑5p 1.76 ± 1.03 0.75 ± 0.56 1.01 0.00031
Table 7 Expression of miRNAs in the miR-17-92 cluster and paralogues according to molecular subtype, using PCR
Expression levels are presented as mean (standard deviation) of normalized PCR quantification cycle (Cq) values based on the average of the normalizer assay 
detected in all samples and the formula: normalized Cq = average Cq (all samples) − assay Cq (sample). Negative PCR expression values indicate lower expression 
levels compared to the normalizer
* False discovery rate (FDR) adjusted p-value for contrast tests comparing miRNA expression levels in one molecular subtype of cancers to the other cancers grouped 
together. E indicates exponential number
MiRNA Molecular subtype Mean (SD) Contrasts p*
miR‑17‑5p Luminal A − 5.49 (0.73) Luminal A vs others 0.066
Luminal B − 4.93 (1.43) Luminal B vs others 0.65
HER2+ − 5.03 (1.70) HER2+ vs others 0.58
Triple‑negative − 3.26 (0.95) Triple‑negative vs others 0.0025
miR‑20a‑5p Luminal A 1.72 (0.68) Luminal A vs others 0.066
Luminal B 2.21 (1.18) Luminal B vs others 0.67
HER2+ 2.15 (1.19) HER2+ vs others 0.65
Triple‑negative 3.45 (1.03) Triple‑negative vs others 0.0053
miR‑92a‑3p Luminal A 1.44 (0.74) Luminal A vs others 0.070
Luminal B 1.75 (1.00) Luminal B vs others 0.58
HER2+ 1.89 (0.97) HER2+ vs others 0.85
Triple‑negative 2.87 (0.90) Triple‑negative vs others 0.0073
miR‑106b‑5p Luminal A − 0.014 (0.55) Luminal A vs others 0.12
Luminal B 0.30 (1.11) Luminal B vs others 0.65
HER2+ 0.54 (1.44) HER2+ vs others 0.91
Triple‑negative 1.10 (0.84) Triple‑negative vs others 0.070
miR‑93‑5p Luminal A 1.20 (0.73) Luminal A vs others 0.070
Luminal B 1.78 (0.97) Luminal B vs others 0.93
HER2+ 1.85 (1.21) HER2+ vs others 0.91
Triple‑negative 2.37 (1.03) Triple‑negative vs others 0.085
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oncogenic activity through binding to and repression of 
the tumor suppressor PTEN and activation of the Akt-
mTOR (mammalian target of rapamycin) pathway to 
promote cell survival [66]. Further, the tumor suppres-
sor p53 is a direct target of miR-25 [67]. MiR-25 has also 
been shown to promote proliferation in triple-negative 
breast cancer cells by repression of the BTG anti-prolif-
eration factor 2 [68] whereas miR-106b has been shown 
to induce proliferation by targeting RB proteins in vari-
ous cancers [69, 70]. MiR-93 has been shown to increase 
proliferation, migration and invasion potential of MCF7 
breast cancer cells and to have many potential targets 
involved in tumor growth, including the large tumor 
suppressor homologue 2 (LATS2) [33]. In summary, the 
miR-17-92 cluster and the miR-17 family of miRNAs 
have been demonstrated to regulate functions at the very 
core of malignancy: invasion, metastasis, cellular prolif-
eration and resistance to apoptosis.
Microarray miRNA profiling of human breast cancer 
has been demonstrated to be an informative tool which 
can be used to classify human breast cancers [19]. How-
ever, interpretation of research data, and implementation 
of miRNA-profiling into clinical practice are complicated 
by the apparent lack of consistency between studies. 
Variation in study size, design and experimental factors 
such as sample type, RNA quality, methods and technol-
ogy platform used is challenging when trying to summa-
rize clinically relevant data on miRNA profiling. Further, 
investigated miRNAs are not identical between studies. 
However, this study using FFPE-tissue, immunohisto-
chemical analyses used in everyday diagnostics and a 
microarray with 94% coverage of human miRNAs, indi-
cates that the miR-17-92 cluster and miR-17-family of 
miRNAs are of special interest in the high grade, triple-
negative tumors with the worst prognosis. Further stud-
ies, including validation in an independent cohort, in situ 
hybridization in tissues and analyses of prediagnostic 
blood samples could be of interest to further evaluate 
the miRNA expression within tumor cells, the tumors’ 
microenvironment and in the circulation, and the poten-
tial of these miRNAs in diagnostic pathology and clinical 
oncology.
Conclusions
In the NOWAC postgenome cohort, archived FFPE 
tissue was found suitable for miRNA analyses using 
microarray and PCR technology. We found the miRNA 




























6 7 8 9 6 7 8 9 7 8 9

































p = 9.40E-6 
r = 0.55
p = 5.08E-6 
r = 0.57
p = 3.08E-6 
Fig. 8 Scatterplots comparing expression levels of individual miRNAs analyzed by microarray and PCR. Expression levels from microarray analyses, 
given as log2 transformed intensity values (Hy3), are plotted against normalized PCR expression for the different miRNAs. Pearson correlation 
coefficients (r) and p‑values are presented in the figure
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and malignant breast tissue. When exploring the miRNA 
expression profiles according to receptor status, histo-
logic grade and molecular subtypes, we found a coor-
dinated clear upregulation of miR-17-5p, miR-20a-5p, 
miR-92a-3p, miR-106b-5p and miR-93-5p of the miR-
17-92 cluster and the miR-17-family in the most aggres-
sive tumors with higher tumor grade and triple-negative 
receptor status. A validation of this pilot study in an inde-
pendent cohort is a focus for future research. Further, 
the diagnostic and functional role of the miR-17-family 
of miRNAs in breast cancer should be further explored, 
where miRNAs’ potential as markers of response to spe-
cific treatments or as biomarkers of breast cancer relapse 
or metastatic disease is highly interesting.
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